

Celldex Therapeutics, Inc. Investor Relations Department 119 Fourth Avenue Needham, MA 02494-2725 United States

Visit IR website ☐ Sign-up for email alerts ☐

NASDAQ: CLDX ¹	
Last Trade:	0.70
Trade Time:	4:00 PM ET Apr 20, 2018
Change:	0.02 🕇 (3.092%)
Day Range	0.69 - 0.75
52-Week Range	0.65 - 3.42
Volume	6,197,051
Market Cap. (\$M)	98.749
Shares Out (M)	141.070

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... (more)

Stock Performance



Press Releases [View all]

Apr 20, 2018

Data from Multiple Celldex Programs

Presented at American Association for

Cancer Research (AACR) Annual Meeting

2018

Apr 16, 2018

Celldex's METRIC Study in Metastatic Triplenegative Breast Cancer Does Not Meet Primary Endpoint

Mar 7, 2018

<u>Celldex Provides Corporate Update and</u> <u>Reports Full Year 2017 Results</u>

Mar 2, 2018

Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference

Nov 30, 2017

<u>Celldex Therapeutics Initiates Phase 1 Study</u> <u>of New Product Candidate CDX-1140 in Solid</u> Tumors

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Fourth Quarter Financial Results

Mar 7, 2018

Annual Report (10-K)

Apr 28, 2017

Definitive Proxy Statement

Nov 7, 2017

Quarterly Report (10-Q)

Aug 8, 2017

Quarterly Report (10-Q)

May 9, 2017

Quarterly Report (10-Q)

